Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease

Bibliography

• NORMAN P: Pulmonary Diseases. Disease Trends and Market Opportunities. Financial Times Business Ltd, (1999) London, UK.
   Google Scholar
• JEFFERY PK: Differences and similarities between chronic obstructive pulmonary disease and asthma. Clin. Exp. Allergy (1999) 29:14–26.
   PubMed Web of Science ®Google Scholar
• SMITH DH, MALONE DC, LAWSON KA et al.:A national estimate of the economic costs of asthma. Am. j Respir Grit. Care Med. (1997) 156:787–793.
   PubMed Web of Science ®Google Scholar
• MANNINO DM, HOMA DM, PERTOWSKI CA et al.:Surveillance for asthma - United States, 1960–1995. Morbid Mortal. Week. Rep: CDC Surveillance Sum. (1998) 47:11–27.
   Google Scholar
• SEARS MR: Descriptive epidemiology of asthma. Lancet (1997) 350:1–4.
   PubMed Web of Science ®Google Scholar
• BARNES PJ, JONSSON B, KLIM JB: Thecosts of asthma. Eur. Respir J (1996) 9:636–642.
   PubMed Web of Science ®Google Scholar
• SIAFAKAS NM: ERS consensus statement: optimal assessment and management of chronic pulmonary disease. Eur. Respir Rev (1996) 6:270–275.
   Google Scholar
• ATS: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am. J Respir. Grit. Care Med. (1995) 152(Suppl.):S77–S121.
   Google Scholar
• HURD S: The impact of COPD on lung health Worldwide: epidemiology and incidence. Chest (2000) 117:1S–4S.
   Google Scholar
• WHO: Life in the 21st century - a vision for all. World Health Report 1998. World Health Organisation, (1998) Geneva, Switzerland.
   Google Scholar
• MURRAY CJ, LOPEZ AD: Mortality bycause for eight regions of the world: Global Burden of Disease Study. Lancet (1997) 349:1269–1276.
   PubMed Web of Science ®Google Scholar
• MURRAY CJ, LOPEZ AD: Evidence-based health-policy lessons from the Global Burden of Disease Study. Science (1996) 274:740–743.
   PubMed Web of Science ®Google Scholar
• CULPITT SV, ROGERS DF: Evaluation of current pharmacotherapy of chronic obstructive pulmonary disease. Expert Opin. Pharmacother. (2000) 1:1007–1020.
   PubMedGoogle Scholar
• CALVERLEY PMA, BARNES PJ: Pro/Con Editorial: Inhaled corticosteroids are/are not beneficial in chronic obstructive pulmonary disease. Am. ..1 Respir Grit. Care Med. (2000) 161:341–344.
   Google Scholar
• •Editorial providing evidence for and against a beneficial effect of steroids in the management of COPD.
   Google Scholar
• MUHSIN M: SmithKline-Beecham R & D Review Meeting London, UK. Ideal Data Base (1998) Current Drugs Ltd, London, UK.
   Google Scholar
• SMITHKLINE-BEECHAM: Research & Development Review - SB Pharmaceuticals Mid Stage Development Portfolio: Products in Phase II Clinical Trials. Company Brochure (1995).
   Google Scholar
• NEW DRUGS IN THE R & D PIPELINE: SmithKline-Beecham Seiyaku. Pharma. _lap. (1997) 15:17.
   Google Scholar
• NEW DRUGS IN THE R & D PIPELINE: SmithKline-Beecham Seiyaku. Pharma. Jap. (1998) 16:17.
   Google Scholar
• HATZELMANN A, SCHUDT D: Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. I Pharmacol Exp. Ther. (2001) 297:267–279.
   PubMed Web of Science ®Google Scholar
• BUNDSCHUH DS, ELTZE M, BARSIG J, WOLLIN L, HATZELMANN A, BEUME R. In vivo efficacy in airway disease models of roflumilast, a novel orally-active PDE4 inhibitor. I Pharmacol Exp. Ther. (2001) 297:280–290.
   PubMed Web of Science ®Google Scholar
• NORMAN P: PDE inhibitors: sustained patenting activity as leading drugs near the market. Expert Opin. Ther. Patents. (2000) 10:1415–1427.
   Web of Science ®Google Scholar
• PILLING D: SB and Glaxo continue strong growth. Pharmaceuticals companies say merger is on track for completion by year-end. Financial Times. (2000) November 1.
   Google Scholar
• BROWN W: Ariflo. 'Drugs (1999) 2:915–924.
   PubMed Web of Science ®Google Scholar
• HO YP: SmithKline-Beecham earnings top expectation. thestreet.com Press Release, October 31(2000).
   Google Scholar
• TORPHY TJ: Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am. J. Respic Grit. Care Med. (1998) 157:351–370.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review of PDE4 by one of the leaders in the field.
   Google Scholar
• MULLER T, ENGELS P, FOZARD JR: Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. Trends. Pharmacol Sci. (1996) 17:294–298.
   PubMed Web of Science ®Google Scholar
• HOUSLAY MD, SULLIVAN M, BOLGER GB: The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv. Pharmacol (1998) 44:225–342.
   PubMedGoogle Scholar
• TEIXEIRA MM, GRISTWOOD RW, COOPER N et al.: Phosphodiesterase (PDE) 4 inhibitors: drugs of the future? Trends. Pharmacol Sci. (1997) 18:164–170.
   PubMed Web of Science ®Google Scholar
• GIEMBYCZ MA: Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here? Drugs (2000) 59:193–212.
   Google Scholar
• KUEHL FA, ZANETTI ME, SODERMAN DD et al.: Cyclic AMP-dependent regulation of lipid mediators in white cells: a unifying concept for explaining the efficacy of theophylline in asthma. Am. Rev Respir. Dis. (1987) 136:210–213.
   PubMed Web of Science ®Google Scholar
• SOUNESS JE, RAO S: Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell. Signalling. (1997) 9:227–236.
   PubMed Web of Science ®Google Scholar
• •Evidence for different conformational states of PDE4 and relevance for the design of selective inhibitors with therapeutic activity..
   Google Scholar
• BARNETTE MS, CHRISTENSEN SB, UNDERWOOD DC etal.: Phosphodiesterase 4: biological underpinnings of the design of improved inhibitors. Pharmacol Res. Commun. (1997) 8:65–73.
   Google Scholar
• HUGHES B, OWENS R, PERRY M et al.:PDE4 inhibitors: the use of molecular cloning in the design and development of novel drugs. Drug. Disc. Today (1997) 2:89–101.
   Web of Science ®Google Scholar
• BARNETTE MS, MANNING CD, CIESLINSKI LB et al.: The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity. Pharmacol Exp. Ther. (1995) 273:674–679.
   PubMed Web of Science ®Google Scholar
• SOUNESS JE, HOUGHTON C, SARDAR N etal.: Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a 'low affinity' phosphodiesterase 4 conformer. Br Pharmacol (1997) 121:743–750.
   Google Scholar
• BARNETTE MS, BARTUS JO, BURMAN M et al.: Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for l3FIlrolipram binding. Biochem. Pharmacol (1996) 51:949–956.
   PubMed Web of Science ®Google Scholar
• SOUNESS JE, GRIFFIN M, MASLEN C eta/.:Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFa generation from human monocytes by interacting with a low-affinity' phosphodiesterase 4 conformer. Br. Pharmacol (1996) 118:649–658.
   Google Scholar
• DUPLANTIER AJ, BIGGERS MS, CHAMBERS RJ et al: Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase Type IV versus l3FIlrolipram binding activity and their relationship to emetic behavior in the ferret. Med. Chem. (1996) 39:120–125.
   Web of Science ®Google Scholar
• BARNETTE MS, GROUS M, CIESLINSKI LB et al.:Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site. I Pharmacol Exp. Ther. (1995) 273:1396–1402.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN SB, GUIDER A, FORSTER CJ et al.: 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma. j Med. Chem. (1998) 41:821–835.
   PubMed Web of Science ®Google Scholar
• MARIVET MC, BOURGUIGNON J-J, LUGNIER C et al.: Inhibition of cyclic adenosine-3',Y-phosphate phosphodiesterase from vascular smooth muscle by rolipram analogues. I Med. Chem. (1989) 32:1450–1457.
   PubMed Web of Science ®Google Scholar
• NORMAN P: PDE4 Inhibitors 1998. Expert Opin. Ther. Patents. (1998) 8:771–784.
   Web of Science ®Google Scholar
• NORMAN P: PDE4 inhibitors 1999. Expert Opin. Ther. Patents. (1999) 9:1101–1118.
   Web of Science ®Google Scholar
• BARNETTE MS, CHRISTENSEN SB, ESSAYAN DM et al.: SB 207499, a potent and selective phosphodiesterase (PDE) IV inhibitor suppresses activities of several immune and inflammatory cells. Am. Respir. Grit. Care Med. (1994) 149:A209. (Abstract).
   Google Scholar
• LALIBERTE F, HAN Y, GOVINDARAJAN A etal.: Conformational difference between PDE4 apoenzyme and holoenzyme. Biochemistry (2000) 39:6449–6458.
   Google Scholar
• TORPHY TJ, CHRISTENSEN SB, BARNETTE MS et al; Molecular basis for an improved therapeutic index of SB 207499, a second generation phosphodiesterase 4 inhibitor. Eur. Respic (1997) 10:313s. (Abstract).
   Google Scholar
• TORPHY TJ, BARNETTE MS, UNDERWOOD DC et al: ArifloTM (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm. Pharmacol Ther. (1999) 12:131–135.
   PubMed Web of Science ®Google Scholar
• TORPHY TJ, STADEL JM, BURMAN M et al.: Co-expression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast. I Biol. Chem. (1992) 267:1798–1804.
   Web of Science ®Google Scholar
• BARNETTE MS, CHRISTENSEN SB, ESSAYAN DM et al: SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. I Pharmacol Exp. Ther. (1998) 284:420–426.
   PubMed Web of Science ®Google Scholar
• ZUSSMAN B, KELLY J, MURDOCH R et al.: Ariflo, a novel and selective oral PDE4 inhibitor, has a favourable metabolic profile with low potential for drug-drug interactions. Am. 1. Respir Grit. Care. Med. (2000) 161:A492. (Abstract).
   Google Scholar
• ZUSSMAN B, KELLY J, MURDOCH R et al.: Ariflo, a novel and selective oral PDE4 inhibitor, has linear pharmacokinetics and high bioavailability. Am. I Respir Grit. Care Med. (2000) 161:A574. (Abstract).
   Google Scholar
• ZUSSMAN B, KELLY J, MURDOCH RD et al.: The pharmacokinetics of Ariflo (SB 207499), an orally-active novel and selective PDE4 inhibitor, are similar after morning and evening dosing. Eur. Respir. 1 (1999) 14:331s. (Abstract).
   Google Scholar
• MURDOCH RD, CLARK D, KELLY J et al.: Ariflo (SB 207499), an orally active, second generation selective PDE4 inhibitor, does not interact with a variety of commonly administered COPD medications. Am. 1. Respir: Grit. Care Med. (1999) 159:A525. (Abstract).
   Google Scholar
• MURDOCH R, KELLY J, CLARK DJ: An orally active, novel and selective PDE4 inhibitor, does not potentiate the anti-coagulatory effect of warfarin in healthy male volunteers. Am. I Respir: Grit. Care Med. (2000) 161:A572. (Abstract).
   Google Scholar
• KELLY J, MURDOCH RD, CLARK DJ et al.: Ariflo, (SB 207499), an orally-active, novel and selective PDE4 inhibitor, has no effect on the steady state pharmacokinetics of digoxin (375 mcg od) in healthy volunteers. Am. 1. Respir Grit. Care Med. (2000) 161:A573. (Abstract).
   Google Scholar
• KELLY J, MURDOCH RD, SCHOFIELD JP et al.: The pharmacokinetic and tolerability profile of cilomilast (Ariflo), unaffected by co-administration of theophylline. Am. I Respir. Grit Care Med. (2001) 163:A278. (Abstract)
   Google Scholar
• MURDOCH R, COWLEY H, WEBBER D etal.: The addition of SB 207499 (Ariflo), a novel and selective PDE4 inhibitor, to oral prednisolone, is safe and well tolerated. Eur. Respir: 1. (1998) 12:362s. (Abstract).
   Google Scholar
• COMPTON C, EDELSON JD, CEDAR E et al.: Cilomilast (Ariflo) 15 mg bid safety in a six month clinical trial program. Am. I Respir: Grit. Care Med. (2001) 163:A909. (Abstract).
   Google Scholar
• SHIMADA T, IWASAKI M, MARTIN MV etal.: Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by emu gene response in Salmonella gphimurium TA 1535/pSK1002. Cancer Res. (1989) 49:3218–3228.
   Google Scholar
• CAMPBELL ME, SPIELBERG SE KALOW W: A urinary metabolite ratio that reflects systemic caffeine clearance. CM]. Pharmacol. Ther. (1987) 42:157–165.
   PubMed Web of Science ®Google Scholar
• VISTISEN K, POULSEN HE, LOFTS: Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. Carcirrogerresis (1992) 13:1561–1568.
   PubMed Web of Science ®Google Scholar
• BUTLER MA, LANG NP, YOUNG JF et al.: Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogerretics (1992) 2:116–127.
   PubMedGoogle Scholar
• GU L, GONZALEZ FJ, KALOW W et al.: Biotransformation of caffeine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP 2E1. Pharmacogerretics (1992) 2:72–77.
   Google Scholar
• FUHR E, DOEHMER J, BATTULA N et al.: Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochem. Pharmacol. (1992) 43:225–235.
   PubMed Web of Science ®Google Scholar
• SARKAR MA, HUNT C, GUZELIAN PS et al.: Characterization of human liver cytochrome P-450 involved in theophylline metabolism. Drug Metab. Disp. (1992) 20:31–37.
   PubMed Web of Science ®Google Scholar
• TJIA JF, COLBERT J, BACK DJ:Theophylline metabolism in human liver microsomes: inhibition studies. 1. Pharmacol. Exp. Ther. (1996) 276:912–917.
   Google Scholar
• HA HR, CHEN J, FREIBURGHAUS AU et al.: Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br 1. Glin. Pharmacol (1995) 39:321–326.
   Google Scholar
• CAMPBELL ME, GRANT DM, INABA Tet al.: Biotransformation of caffeine, paraxanthine, theophylline and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome P450 in human liver microsomes. Drug Metab. Disp. (1987) 15:237–249.
   Google Scholar
• ROBS ON RA, MATTHEWS AE MINERS JO et al.: Characterization of theophylline metabolism in human liver microsomes. Br 1. Cliii. Pharmacol (1987) 24:293–300.
   Google Scholar
• ROBS ON RA, MINERS JO, MATTHEWS AP etal.: Characterization of theophylline metabolism by human liver microsomes. Biochem. Pharmacol. (1988) 37:1651–1659.
   Google Scholar
• HUNT SN, JUSKO WJ, YURCHAK AM: Effect of smoking on theophylline disposition. OM. Pharmacol Ther. (1976) 19:546–561.
   Web of Science ®Google Scholar
• POWELL JR, THIERCELIN JF, VOZEH S et al.: The influence of cigarette smoking and sex on theophylline disposition. Am. Rev Respir Dis. (1977) 116:17–23.
   PubMed Web of Science ®Google Scholar
• POWELL JR, VOZEH S, HOPEWELL P etal.: Theophylline disposition in acutely ill hospitalized patients. The effect of smoking, heart failure, severe airway obstruction, and pneumonia. Am. Rev. Respir: Dis. (1978) 118:229–238.
   Google Scholar
• JUSKO WJ, SCHENTAG JJ, CLARK JH etal.: Enhanced biotransformation of theophylline in marihuana and tobacco smokers. OM. Pharmacol Ther. (1978) 24:405–410.
   Google Scholar
• JUSKO WJ: Influence of cigarette smoking on drug metabolism in man. Drug Metab. Rev (1979) 9:221–236.
   PubMed Web of Science ®Google Scholar
• KELLY J, MURDOCH RD, CLARK DJ et al.: Smoking status has no effect on the clearance of a single dose of Ariflo (SB 207499, 15 mg), an orally active, novel, second generation PDE4 inhibitor in healthy male volunteers. Am. I Respir. Grit. Care Med. (1999) 159:A807. (Abstract).
   Google Scholar
• MURDOCH RD, COWLEY H, UPWARD J et al.: The safety and tolerability of ArifloTM (SB 207499), a novel and selective phosphodiesterase 4 inhibitor, in healthy male volunteers. Am. I Respir: Grit. Care. Med. (1998) 157:A409. (Abstract).
   Google Scholar
• COMPTON CH, CEDAR E, NIEMAN RB et al.: ArifloTM improves pulmonary function in patients with asthma: results of a study in patients taking inhaled corticosteroids. Am. I Respir Grit. Care. Med. (1999) 159:A624. (Abstract).
   Google Scholar
• COMPTON C, DUGGAN M, CEDAR E et al.: Safety of Ariflo in a 12-month study of patients with asthma. Am. I Respir: Grit. Care Med. (2000) 161:A200. (Abstract).
   Google Scholar
• NIEMAN RB, FISHER BD, AMIT 0 etal.: SB 207499 (ArifloTM), a second generation, selective oral phosphodiesterase *type 4 (PDE4) inhibitor, attenuates exercise-induced bronchoconstriction in patients with asthma. Am. 1. Respir. Grit. Care. Med. (1998) 157:A413. (Abstract).
   Google Scholar
• COMPTON CH, CEDAR E, NIEMAN RB et al.: SB 207499 improves pulmonary function in patients with asthma receiving concomitant inhaled corticosteroids. Eur. Respir J. (1999) 14:288s. (Abstract).
   Google Scholar
• COMPTON C, DUGGAN M, CEDAR E et al.: Ariflo efficacy in a 12-month study of patients with asthma. Am. j Respir. Grit. Care Med. (2000) 161:A505. (Abstract).
   Google Scholar
• COMPTON CH, GUBB J, CEDAR E et al:The efficacy of Ariflorm (SB 207499), a second generation, oral PDE4 inhibitor, in patients with COPD. Am. j Respir. ('nt. Care. Med. (1999) 159:A806. (Abstract).
   Google Scholar
• COMPTON CH, GUBB J, CEDAR E et al.: SB 207499, second generation, oral PDE4 inhibitor, first demonstration of efficacy in patients with COPD. Eur. Respir. 1. (1999) 14:331s. (Abstract).
   Google Scholar
• NIEMAN RB, TANEJA DT, AMIT 0 et al.: The effects of low-dose SB 207499, a second-generation, oral PDE4 inhibitor, in patients with COPD. Eur. Respir 1. (1999) 14:331s. (Abstract).
   Google Scholar
• WARE JE, SHERBOURNE CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care. (1992) 30:473–483.
   Google Scholar
• COMPTON CH, GUBB J, CEDAR E et al.: Ariflo (SB 207499), a second generation, oral PDE4 inhibitor, improves quality of life in patients with COPD. Am. Respir: Grit. Care Med. (1999) 159:A522. (Abstract).
   Google Scholar
• EDELSON JD, COMPTON C, NIEMAN R et al.: Cilomilast (Ariflo) a potent, selective phosphodiesterase 4 inhibitor, reduces exacerbations in COPD patients: results of a 6 month trial. Am. 1. Respir. Grit. Care Med. (2001) 163:A771. (Abstract).
   Google Scholar
• EDELSON JD, COMPTON C, NIEMAN R et al.: Cilomilast (Ariflo), a potent, selective inhibitor of phosphodiesterase 4, improves lung function in patients with COPD: results of a 6-month trial. Am. 1. Respir. Grit. Care Med. (2001) 163:A277. (Abstract).
   Google Scholar
• •Phase III study reporting efficacy of cilomilast in patients with stable COPD.
   Google Scholar
• EDELSON JD, COMPTON C, NIEMAN R et al.: Cilomilast (Ariflo) improves health status in patients with COPD: results of a 6 month trial. Am. J. Respir Grit. Care Med. (2001) 163:A277. (Abstract).
   Google Scholar
• KELLY J, MURDOCH RD, SCHOFIELD JP et al.: The safety of cilomilast (Ariflo) co-administration with oral theophylline: cardiovascular profile. Am. j Respir Crit. Care Med. (2001) 163:A79. (Abstract).
   Google Scholar
• SULLIVAN SD, RAMSEY SD, LEE TA: The economic burden of COPD. Chest (2000) 117:5S–9S.
   Google Scholar
• BAGCHI I, BAKST AW, EDELSTON JE et al.: Cilomilast reduces healthcare resource utilization of chronic obstructive pulmonary disease patients. Am. j Respir Grit. Care Med. (2001) 163:A507. (Abstract).
   Google Scholar
• WANG P, WU P, OHLETH KM et al.: Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Pharmacol (1999) 56:170–174.
   Web of Science ®Google Scholar
• MANNING CD, BURMAN M, CHRISTENSEN SB et al.:Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br. j Pharmacol (1999) 128:1393–1398.
   PubMed Web of Science ®Google Scholar
• •In vitro study showing that TNFa release from human monocytes and antigen-induced proliferation of human T-lymphocytes correlates with the inhibition of PDE4A/B.
   Google Scholar
• HANSEN G, JIN SC, UMETSU DT etal.: Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. Proc. Natl. Acad. Sci. USA (2000) 97:6751–6757.
   Google Scholar
• •Thought-provoking study in which antigen-induced eosinophilia and other indices of allergic inflammation are unaffected in PDE4D knockout mice.
   Google Scholar
• LAZZERI N, BELVISI MG, PATEL HJ et al.: Effects of prostaglandin E2 and cAMP-elevating drugs on GM-CSF release by human airway smooth muscle. Am. j. Respir Cell Ma Biol. (2001) 24:44–48.
   PubMed Web of Science ®Google Scholar
• AMMIT AJ, HOFFMAN RK, AMRANI A etal.: Tumor necrosis factor-a-induced secretion of RANTES and interleukin-6 from human airway smooth muscle cells. Modulation by cyclic adenosine monophosphate. Am. 1. Respir Cell Ma Biol. (2000) 23:794–802.
   Google Scholar
• IRANI C, AMMIT AJ, O'NEILL GM etal.: CRE, but not AP-1, NF-icB or C/EBP, mediates cAMP-induced IL-6 gene expression in human airway smooth muscle cells. Am. 1. Respir Grit. Care Med. (2001) 163:A778. (Abstract).
   Google Scholar
• PANETTIERI RA, ESZTERHAS A, CIESLINSKI LB et al:Ariflo (SB 207499) modulates human airway smooth muscle cell proliferation induced by mitogens. Am. Respir. Grit. Care Med. (2000) 161:A697. (Abstract).
   Google Scholar
• PANETTIERI RA, ESZTERHAS A, ANDERSON C et al.: Ariflo (SB 207499), a selective phosphodiesterase (PDE) 4 inhibitor, inhibits human airway smooth muscle (HASM) cell proliferation induced by mitogens. Eur. Respir. 1 (2000) 16:370s. (Abstract).
   Google Scholar
• UNDERWOOD DC, BOCHNOWICZ S, OSBORN RR et al.: Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig. 1. Pharmacol Exp. Ther. (1998) 287:988–995.
   Google Scholar
• UNDEM B, HAY DWP, TORPHY TJ: Ariflo (SB 207499), a selective phosphodiesterase (PDE) 4 inhibitor, modulates neuronal responses in guinea-pig and human airways in vitro. Eur. Respir. (2000) 16:539s. (Abstract).
   Google Scholar
• CHIPAPPARA G, MERENDINO AM, CHIMENTI L et al.: Cilomilast (Ariflo) reduces TNFa and GM-CSF release by airway cells isolated from COPD patients. Am. J. Respir Grit. Care Med. (2001) 163:A278. (Abstract).
   Google Scholar
• AU BT, TEIXEIRA MM, COLLINS PD et a].: Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol. Br j Pharmacol. (1998) 123:1260–1266.
   Google Scholar
• MALUS E, CHERAPANOV V, ARORA A et al.: Selective inhibition of neutrophil function by the phosphodiesterase 4 inhibitor SB 207499. Am. 1. Respir Grit. Care Med. (2001) 163: (In press)
   Google Scholar
• OWEN CA, BARNETTE MS, CAMPBELL EJ et al.: Cilomilast (Ariflo) inhibits neutrophil pro-inflammatory activities. Am. j Respir. Grit. Care Med. (2001) 163:A348. (Abstract).
   Google Scholar
• KOHYAMA T, LIU XD, ETRL RF et al.: PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels: potential antifibrotic effects. Am. I Respir Grit. Care Med. (2000) 161:A440. (Abstract).
   Google Scholar
• KOHYAMA T, ZHU YK, WEN FQ et al.: The phosphodiesterase IV inhibitor SB 207499 inhibits cytokine and elastase induced fibroblast degradation of three dimensional collagen gels. Eur. Respir. (2000) 16:250s. (Abstract).
   Google Scholar
• MINNICOZZI M, FINE J, KREUTNER W et al.: Inhibition of LPS-induced pulmonary inflammation by beclomethasone and SB 207499 in rats. Am. Respir Grit. Care Med. (2000) 161:A183. (Abstract).
   Google Scholar
• SPICER D, FITZGERALD ME CLARKE E et al.: Efficacy of the selective phosphodiesterase (PDE) 4 inhibitor, BAY 19–8004, in a rat model of neutrophilic lung inflammation. Am. I Respir Grit. Care Med. (2000) 161:A578. (Abstract).
   Google Scholar
• RUSH AK, LIU YC, HAY DWP et al.: Influence of the selective phosphodiesterase (PDE) 4 inhibitor, Ariflo (SB 207499), on expression of mucin (MUC) gene 5AC in airways of allergic Brown-Norway (BN) rats. Eur. Respir. j. (2000) 16:74s. (Abstract).
   Google Scholar
• PLANQUOIS JMS, RUFFIN Y, DOHERTY A: Anti-inflammarory effect of selective PDE inhibitors on ear inflammation in Swiss mice. Am. j. Respir Grit. Care Med. (2000) 161:A326. (Abstract).
   Google Scholar
• WOOLLEY ST, WEYMAN-JONES C, YOUNG A: A comparison of the effect of PDE4 inhibitors on neutrophilia and cytokine expression in a murine model of LPS-induced lung inflammation. Eur. Respir j. (2000) 16:539s. (Abstract).
   Google Scholar
• GRISWOLD DE, WEBB EE BADGER AM et al.: SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. j. Pharmacol. Exp. Ther. (1998) 287:705–711.
   Google Scholar
• DEMARSH PL, SUCOLOSKI SK, TAL-SINGER R et al.: Effect of cilomilast, an orally-active, selective PDE4 inhibitor in a murine viralibacterial co-infection model. Am. J. Respir. Grit. Care Med. (2001) 163:A381. (Abstract).
   Google Scholar
• •First demonstration in a murine model of viral/bacterial co-infection that a PDE4 inhibitor does not increase susceptibility to viral or bacterial challenge.
   Google Scholar
• LIU Q, FUJIMURA M, TACHIBANA H et al.: Effect of a selective PDE4 inhibitor, SB 207499, on airway cough hypersensitivity induced by allergic eosinophilic bronchitis. Eur. Respir (2000) 16:539s. (Abstract).
   Google Scholar
• OSBORN RR, UNDERWOOD DC, KOTZER CJ: Correlation of inhaled antigen- or cysteinyl leukotriene-induced hypertussive activity with airway eosinophilia in guinea-pigs. Am. I Respir. Grit. Care Med. (2001) 163:A144. (Abstract).
   Google Scholar
• UNDERWOOD DC, OSBORN RR, BOCHNOWICZ S et al.: Ariflo (SB 207499) inhibits airway neutrophilia, inflammatory cytokine production and matrix metalloproteinase-9 activity in the guinea-pig. Am. j. Respir. Grit. Care Med. (2000) 161:A492. (Abstract).
   Google Scholar
• DENT G, POPPE H, EGERLAND J et al.: Effects of a selective PDE4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs. Pulm. Pharmacol. Ther. (1998) 11:13–21.
   PubMed Web of Science ®Google Scholar
• UNDERWOOD DC, OSBORN RR, BOCHNOWICZ S et al.: The therapeutic activity of SB 207499 (Ariflo), a second generation phosphodiesterase 4 (PDE4) inhibitor, is equivalent to that of prednisolone in models of pulmonary inflammation. kn. j Respir Grit. Care Med. (1998) 157:A827. (Abstract).
   Google Scholar
• GRISWOLD DE, MARTIN LD, TORPHY TJ.:Ariflo (SB 207499) is a potent inhibitor of leukotriene 134-induced mobilization of peripheral blood neutrophils in rabbits. Am. I Respir. Grit. Care Med. (1999) 160:A90. (Abstract).
   Google Scholar
• PRUNIAUX MP, MOTTON G, PLANQUOIS JM et al.: The selective phosphodiesterase 4 inhibitor CI-1044 (PD189659) inhibits LPS-induced neutrophil recruitment and TNFa release in rat airways. Am. j. Respir Grit. Care Med. (2001) 163:A991. (Abstract).
   Google Scholar
• HOPPE H, MARX D, HEER S et al.: Effects of s selective PDE4 inhibitor AWD 12–281 in comparison with SB 207499 and roflumilast on tracheal phenol red secretion in mice and LPS-induced neutrophilia in Lewis rats and domestic pigs. Am. j. Respir. Grit. Care Med. (2001) 163:A994. (Abstract).
   Google Scholar
• JONES H, PAUL W, PAGE C. Effect of the phosphodiesterase (PDE4) inhibitor Ariflo on polymorphonuclear leukocyte (PMN) trapping in rabbit pulmonary circulation. Am. J. Respir. Grit. Care Med. (2001) 163:A993. (Abstract).
   Google Scholar
• MORCILLO EJ, CORTIJO J, MTNEZ-LOSA et al.:Effects of selective phosphodiesterase 4 inhibitors on functional responses of human neutrophils and eosinophils. Am. j. Respir Grit. Care Med. (2001) 163:A993. (Abstract).
   Google Scholar